ICGC Pancreatic Adenocarcinoma

Overview

The ICGC Pancreatic Adenocarcinoma dataset (cBioPortal study ID: paad_icgc) is a multi-institutional whole-genome sequencing cohort assembled under the International Cancer Genome Consortium (ICGC). It encompasses two major sub-cohorts: the Australian pancreatic cancer genome initiative (PACA-AU, n=375) and the Canadian pancreatic cancer genome project (PACA-CA, n=232), together comprising approximately 607 patients with pancreatic ductal adenocarcinoma (PAAD). The dataset is available on cBioPortal with reference genome hg19.

Composition

  • Cancer type: Pancreatic Adenocarcinoma (PAAD)
  • PACA-AU sub-cohort: ~375 patients from Australia
  • PACA-CA sub-cohort: ~232 patients from Canada
  • Total: ~607 patients with matched genomic and (in a subset) survival data
  • Assay: Whole-genome sequencing
  • Reference genome: hg19

Assays / panels (linked)

  • Whole-genome sequencing (WGS) — high-depth tumor/normal paired WGS enabling comprehensive detection of somatic SNVs, indels, copy number alterations, and structural variants.

Papers using this cohort

Notable findings derived from this cohort

  • Used as part of a pooled 950-patient external validation cohort (together with paad_tcga and the Sausen resectable cohort) to validate KRAS allele-specific survival associations in PDAC; 855 patients with matched genomic and survival data were analyzed PMID:39214094.
  • In the pooled external cohort, KRASG12D was associated with the worst median overall survival (15.6 months) compared to KRASG12R (20.8 months), KRASG12V (22.4 months), and KRASWT (27 months; log-rank p=0.006) PMID:39214094.
  • Multivariate analysis in the pooled cohort confirmed KRASG12R (HR 0.77, 95% CI 0.60–0.99, p=0.038) and KRASG12V (HR 0.71, 95% CI 0.58–0.88, p=0.02) as independently predictive of better overall survival relative to KRASG12D PMID:39214094.
  • Absence of tumor suppressor co-mutations (TP53/SMAD4/CDKN2A) was independently associated with improved OS in the external multi-cohort validation (HR 0.72, 95% CI 0.56–0.92, p=0.009) PMID:39214094.
  • Used for WES of 142 pancreatic ductal adenocarcinoma tumors; identified KRAS, TP53, SMAD4, CDKN2A mutations and novel axon-guidance pathway genes PMID:23103869

Sources

  • cBioPortal study page: https://www.cbioportal.org/study/summary?id=paad_icgc
  • ICGC Data Portal: https://dcc.icgc.org/projects/PACA-AU and https://dcc.icgc.org/projects/PACA-CA

This page was processed by crosslinker on 2026-05-04. - PMID:23103869

This page was processed by wiki-cli on 2026-05-06.